Search This Blog

Wednesday, November 18, 2026

'Should All Adults Be Screened for Lipoprotein(a)?'

 As a drug targeting lipoprotein(a), or Lp(a), failed to prevent cardiovascular events in a closely-watched clinical trial, some experts are questioning recent national guidelines recommending that all adults be screened for it.

Back in March, a collaboration of 11 cardiology-related medical societies strongly recommended, for the first time, that all adults have their blood tested for Lp(a) -- also referred to as "Little a" -- at least once.

Higher scores, the committee said, reveal patients at much higher risk of developing atherosclerotic cardiovascular disease, incentivizing more aggressive management strategies, such as further lowering higher LDL cholesterol, HbA1c, body mass index, and other risks. The guidelines followed the European Atherosclerosis Society's similar recommendation in 2022 and the European Society of Cardiology's reinforcement in 2025.

But many prominent physicians say they are confused or are outright opposed to adding such a universal test. They argue that Lp(a), a heart disease risk marker known for years, is genetically inherited and not affected by LDL, diet, exercise or weight loss, and stays roughly the same through life.

They say the relationship to one's actual risk is unclear because Lp(a) may not necessarily be the cause of disease, but rather, may be related to something that is.

And there's not much one can do about a high score beyond what doctors normally recommend to reduce heart disease and stroke risks in their patients.

On top of that, CMS is allowing regional variation in whether Medicare covers the test, meaning that some seniors will have to pay for it out of pocket, depending on where they live.

"A lot of people are going to be very unnecessarily worried about a useless test that we should not be ordering or recommending in the first place," Rita Redberg, MD, MSc, a preventive cardiologist at the University of California San Francisco and former editor of JAMA Internal Medicine, told MedPage Today.

"It's certainly not going to make a difference in people once they pass age 50. You should be on a healthy lifestyle program no matter what your 'little a' is," Redberg said.

James Stein, MD, a cardiologist and emeritus professor at the University of Wisconsin in Madison, who has written several Substack blogs opposing universal use of the Lp(a) test, told MedPage Today the guidelines have "done a real disservice to the entire medical community by recommending widespread population screening because it creates a lot of anxiety."

"It also leads to a large downstream test cascade ... most of which is not indicated at all, and some of which actually puts you at additional risk for more problems," Stein said.

Then why did the committee make this recommendation?

"In general, there's been a 3-to-5-year push to do more Lp(a) testing, part of which is because there's a bias towards action. Let's do more. Let's prevent more disease," Stein said. "Part of it is because there's been some intellectual seeding, getting all of us ready for the Lp(a) lowering drugs, which a majority of people thought would show reduction in cardiac events."

In the HORIZON trial, the antisense oligonucleotide drug pelacarsen reduced Lp(a) levels, but it failed to reduce major cardiovascular events. That was a huge disappointment to researchers who had high hopes the drug would dramatically shrink cardiovascular death, strokes, and emergency cardiac interventions. If it had, it would have provided an important tool in the fight against cardiovascular disease.

But now, clinicians may find themselves at a loss for what to do about patients with a high Lp(a).

Stein remembers a recent clinic when three patients with no other cardiac risk factors "came in crying. Each one brought in a letter (showing their high scores)."

A woman in her early 70s had an extremely high score, above 350 nmol/l, with no family history and no other risk factors, and one of her children also had a high score, Stein said.

"'I can't believe I gave this to my child,' she told me," Stein said. "Now she is a healthy woman who feels like she has a sword dangling over her head. She does not."

Jason Goldman, MD, immediate past president of the American College of Physicians and an internist in Coral Springs, Florida, prefers recommending a coronary calcium CT score rather than an Lp(a), and was glad that at least the committee mentioned that option in its new guidelines.

"I am less enthusiastic about saying 'Little a' needs to be checked for everyone once because we don't have a treatment to lower it and improve outcomes, but we do have a treatment to lower LDL and cardiovascular disease," Goldman told MedPage Today. "CT calcium, I think, should be ordered on everyone, when appropriate."

He wishes the committee would reconsider its recommendation, especially in light of the HORIZON trial.

At the same time, several doctors told MedPage Today they welcomed the guidelines in their practices.

Jordan Rennicke, MD, a family medicine physician in Johnson City, Tennessee, orders Lp(a) draws for all his patients. And a few times, scores for patients without any risk factors including family history of cardiovascular disease have come back particularly high.

He knows that can "open up a can of worms," but he told MedPage Today he "values the information tremendously because then I can have a more informed discussion with my patients."

Karl Nadolsky, DO, an endocrinologist in Holland, Michigan, also checks all his patients. "It tells us who is carrying an extra inherited risk" that other scores don't show.

Roger Blumenthal, MD, chair of the guidelines committee and a Johns Hopkins cardiologist, said anticipation of positive pelacarsen trial results had nothing to do with the Lp(a) testing recommendation.

He said there's "overwhelming evidence from a multitude of studies that Lp(a) is a strong causal risk factor for atherosclerosis and aortic valve calcification and aortic valve stenosis."

The European societies' recommendations were particularly influential, he told MedPage Today. "We felt there are so many people who get cardiovascular disease at an earlier age than expected, and one common denominator is that they have a higher Lp(a). We felt it is a very reasonable test to do one time."

"Maybe some people say, well, you didn't have to have it as your strongest recommendation, you could make it a class 2A, and I certainly can understand that. But our colleagues across the pond have said the same thing ... that it's a good way to identify people who need to improve their lifestyle habits, that they may be at higher risk of atherosclerosis and aortic valve disease."

"And maybe we can do a better job of motivating people to improve their diet and exercise, and if you lower cholesterol significantly, you seem to neutralize most of the risk associated with a higher Lp(a)," he said.

Blumenthal emphasized that the "committee's guideline is not a rule. We're not saying that you have to do that. It's a simple blood test and it lets me know whether I take after my uncle or aunt who had a stroke or a heart attack at age 50. Then yeah, sure. Let's check it."

Blumenthal said in his own practice, he and many Johns Hopkins colleagues typically do not go by the new guideline to order Lp(a) blood screening for everybody. In his own practice, he orders it for patients who want to know their score, or if there's obvious risk factors like family history.

"There's a lot of well-meaning people on all sides," he said. "Some feel like if you measure anything, you're going to necessarily alarm people. But our feeling is that most people would like to know if they may have a factor that increases their risk, and if it does, then maybe that'll be the extra motivation."

"I understand there are other points of view and concerns," he said.

https://www.medpagetoday.com/cardiology/generalcardiology/123952

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.